TDMS Study 05134-02 Pathology Tables
INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
1,3 BUTADIENE (BUTADIENE)
NTP Experiment-Test: 05134-02 Report: PEIRPT03
Study Type: CHRONIC Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
Facility: Battelle Northwest
Chemical CAS #: 106-99-0
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 70 70 70 70 70 90
Scheduled Sacrifice 20 20 20 20 20 10
Early Deaths
Moribund 10 10 14 31 37 46
Dead 3 7 11 8 12 33
Accident 1 1 1
Survivors
Terminal Sacrifice 37 33 24 11
Animals Examined Microscopically 70 70 70 70 70 90
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (61) (41) (47) (45) (58) (89)
Acanthosis 1 (2%)
Gallbladder (66) (44) (41) (43) (49) (64)
Hyperplasia 1 (2%) 3 (7%)
Inflammation 1 (2%) 1 (2%) 2 (5%) 1 (2%)
Intestine Large, Cecum (68) (46) (46) (47) (57) (78)
Hemorrhage 1 (2%)
Intestine Large, Colon (68) (48) (47) (47) (58) (83)
Endothelium, Hyperplasia 1 (2%)
Intestine Small, Ileum (68) (46) (43) (47) (55) (75)
Inflammation, Chronic 1 (2%)
Peyer's Patch, Hyperplasia 1 (2%)
Intestine Small, Jejunum (67) (45) (44) (47) (54) (70)
Hemorrhage 2 (3%)
Peyer's Patch, Hyperplasia 1 (2%)
Liver (69) (52) (51) (61) (61) (90)
Angiectasis 5 (10%) 1 (2%) 3 (5%) 2 (3%) 1 (1%)
Basophilic Focus 1 (1%) 2 (4%) 1 (2%) 4 (7%) 2 (3%) 1 (1%)
Clear Cell Focus 2 (3%) 1 (2%) 1 (2%)
Degeneration, Fatty 2 (3%) 2 (4%) 1 (2%) 8 (13%) 4 (7%)
Eosinophilic Focus 5 (7%) 12 (23%) 19 (37%) 11 (18%) 5 (8%) 2 (2%)
Hematopoietic Cell Proliferation 3 (4%) 6 (12%) 1 (2%) 11 (18%) 14 (23%) 10 (11%)
Infarct 1 (2%)
Inflammation, Chronic 1 (1%) 1 (2%) 1 (1%)
Inflammation, Focal, Granulomatous 1 (1%) 1 (2%) 1 (2%)
Mixed Cell Focus 1 (2%) 1 (2%) 1 (2%) 1 (1%)
Necrosis 2 (3%) 2 (4%) 7 (14%) 5 (8%) 22 (36%) 19 (21%)
Pigmentation, Bile 1 (2%)
Thrombosis 1 (2%) 1 (1%)
Biliary Tract, Cyst 1 (1%) 1 (2%) 1 (2%) 2 (2%)
Biliary Tract, Hyperplasia 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Centrilobular, Degeneration, Fatty 1 (2%) 1 (2%) 3 (3%)
Centrilobular, Necrosis 1 (2%) 4 (7%) 7 (8%)
Mesentery (12) (13) (16) (9) (15) (6)
Fat, Angiectasis 3 (25%) 3 (23%) 4 (25%) 3 (33%) 1 (7%)
Fat, Ectopic Tissue 1 (8%)
Fat, Hemorrhage 1 (8%) 1 (6%) 2 (13%)
Fat, Inflammation, Chronic 4 (33%) 3 (23%) 7 (44%) 2 (22%) 7 (47%) 1 (17%)
Fat, Necrosis 8 (67%) 6 (46%) 6 (38%) 3 (33%) 7 (47%)
Pancreas (69) (49) (47) (48) (59) (88)
Acinus, Atrophy 3 (4%) 3 (6%) 5 (11%) 2 (3%) 1 (1%)
Acinus, Focal Cellular Change 3 (4%) 5 (10%) 3 (6%) 3 (6%) 1 (2%)
Acinus, Hyperplasia 1 (1%) 1 (2%) 1 (2%)
Acinus, Infarct 1 (1%)
Acinus, Inflammation, Chronic 2 (3%) 3 (6%)
Duct, Cyst 2 (3%) 2 (4%) 1 (1%)
Salivary Glands (70) (49) (50) (49) (60) (89)
Atrophy, Focal 1 (2%)
Inflammation 3 (4%) 4 (8%)
Inflammation, Chronic 1 (2%)
Stomach, Forestomach (70) (50) (57) (68) (70) (89)
Cyst Epithelial Inclusion 1 (2%)
Mineralization 1 (2%)
Ulcer 2 (3%) 2 (4%) 1 (2%) 3 (4%) 5 (7%) 14 (16%)
Epithelium, Hyperplasia 4 (6%) 5 (10%) 4 (7%) 8 (12%) 18 (26%) 56 (63%)
Stomach, Glandular (69) (49) (58) (68) (68) (86)
Hemorrhage 1 (2%) 2 (2%)
Inflammation, Suppurative 1 (2%)
Mineralization 1 (1%)
Pigmentation, Hemosiderin 2 (3%) 2 (4%) 1 (2%) 2 (3%) 5 (7%) 4 (5%)
Ulcer 2 (3%) 1 (2%) 1 (2%) 2 (3%) 6 (9%) 2 (2%)
Epithelium, Hyperplasia 1 (1%)
Tooth (4) (5) (1)
Developmental Malformation 1 (25%)
Inflammation 3 (75%) 4 (80%) 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (1) (1) (1) (1)
Inflammation 1 (100%) 1 (100%)
Mineralization 1 (100%)
Heart (70) (50) (50) (59) (70) (90)
Cardiomyopathy 4 (6%) 2 (4%) 1 (2%) 4 (7%) 2 (2%)
Infiltration Cellular, Mixed Cell 1 (1%)
Mineralization 2 (4%) 2 (3%) 2 (3%) 11 (12%)
Necrosis 2 (3%) 1 (1%) 3 (3%)
Atrium, Thrombosis 2 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM - CONT
Endothelium, Hyperplasia 2 (4%) 1 (2%) 4 (7%) 9 (13%) 9 (10%)
Pericardium, Inflammation, Chronic 1 (2%)
Pericardium, Fat, Necrosis 1 (2%)
Perivascular, Inflammation 1 (1%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (70) (49) (48) (49) (60) (88)
Cyst 1 (2%) 4 (8%) 1 (2%)
Focal Cellular Change 3 (6%)
Hematocyst 1 (2%)
Hematopoietic Cell Proliferation 1 (1%) 1 (2%) 4 (8%) 5 (8%) 2 (2%)
Hemorrhage 1 (1%)
Hyperplasia 3 (4%) 2 (4%) 2 (3%) 1 (1%)
Hypertrophy 1 (1%) 3 (6%) 1 (2%) 3 (6%) 3 (5%)
Capsule, Hyperplasia 2 (4%)
Adrenal Gland, Medulla (70) (48) (47) (45) (60) (86)
Cyst 1 (2%)
Hematopoietic Cell Proliferation 1 (1%)
Hyperplasia 3 (4%) 1 (2%) 1 (2%) 2 (4%)
Islets, Pancreatic (69) (49) (46) (47) (59) (88)
Hyperplasia 2 (3%) 2 (4%)
Parathyroid Gland (57) (40) (33) (39) (47) (77)
Cyst 1 (3%) 1 (1%)
Pituitary Gland (70) (49) (48) (47) (58) (80)
Pars Distalis, Angiectasis 1 (1%) 2 (4%) 3 (6%) 1 (2%)
Pars Distalis, Cyst 1 (2%) 1 (2%) 1 (2%) 2 (3%)
Pars Distalis, Hemorrhage 1 (2%)
Pars Distalis, Hyperplasia 13 (19%) 19 (39%) 10 (21%) 9 (19%)
Pars Intermedia, Hyperplasia 2 (4%) 1 (2%)
Thyroid Gland (69) (49) (49) (49) (59) (88)
Cyst 1 (1%) 6 (12%) 1 (2%) 4 (8%) 1 (2%)
Inflammation 2 (3%) 2 (4%) 2 (4%)
C-Cell, Hyperplasia 1 (2%)
Follicular Cell, Hyperplasia 11 (16%) 10 (20%) 13 (27%) 6 (12%) 2 (3%) 1 (1%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (69) (59) (58) (70) (70) (89)
Angiectasis 5 (7%) 7 (12%) 3 (5%) 13 (19%) 16 (23%) 17 (19%)
Atrophy 4 (6%) 19 (32%) 33 (57%) 51 (73%) 59 (84%) 79 (89%)
Cyst 16 (23%) 29 (49%) 21 (36%) 19 (27%) 12 (17%) 13 (15%)
Metaplasia, Osseous 1 (2%)
Mineralization 1 (2%)
Corpus Luteum, Hyperplasia 1 (2%)
Germinal Epithelium, Hyperplasia 2 (3%) 3 (5%) 8 (14%) 15 (21%) 17 (24%) 20 (22%)
Granulosa Cell, Hyperplasia 1 (1%) 2 (3%) 3 (4%) 5 (7%) 3 (3%)
Uterus (70) (50) (60) (69) (70) (88)
Angiectasis 3 (4%) 8 (16%) 10 (17%) 6 (9%) 2 (3%)
Atrophy 1 (1%) 1 (2%) 1 (1%) 11 (16%) 49 (56%)
Cyst 1 (1%) 1 (1%) 1 (1%)
Dilatation 2 (3%) 2 (4%)
Hemorrhage 1 (2%) 2 (3%) 1 (1%)
Hyperplasia, Cystic 63 (90%) 48 (96%) 50 (83%) 58 (84%) 30 (43%)
Hyperplasia, Histiocytic 1 (1%)
Inflammation 1 (1%) 1 (2%)
Thrombosis 1 (1%) 1 (1%)
Arteriole, Hypertrophy 1 (1%) 1 (2%)
Cervix, Cyst 1 (2%)
Muscularis, Hyperplasia 1 (2%) 1 (1%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (70) (49) (48) (59) (70) (89)
Angiectasis 1 (2%)
Atrophy 12 (13%)
Fibrosis 1 (2%) 1 (2%) 1 (1%)
Hyperplasia 4 (6%) 5 (10%) 9 (19%) 18 (31%) 18 (26%) 20 (22%)
Necrosis 2 (2%)
Lymph Node (70) (50) (50) (60) (69) (89)
Iliac, Hyperplasia 1 (2%)
Pancreatic, Hyperplasia 1 (2%)
Renal, Hyperplasia 1 (2%) 1 (1%)
Lymph Node, Bronchial (58) (42) (42) (41) (46) (62)
Congestion 1 (2%) 1 (2%) 2 (3%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%) 2 (4%)
Hyperplasia 9 (16%) 10 (24%) 6 (14%) 1 (2%) 1 (2%)
Inflammation 1 (2%)
Lymph Node, Mandibular (53) (42) (46) (49) (54) (64)
Congestion 1 (2%)
Hematopoietic Cell Proliferation 2 (4%) 3 (6%) 2 (4%)
Hyperplasia 8 (15%) 5 (12%) 3 (7%) 5 (10%) 2 (4%)
Hyperplasia, Histiocytic 3 (5%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Hyperplasia, Plasma Cell 1 (2%)
Necrosis 1 (2%)
Lymph Node, Mediastinal (39) (29) (33) (44) (51) (74)
Angiectasis 1 (3%)
Congestion 1 (3%) 1 (2%) 4 (5%)
Hematopoietic Cell Proliferation 2 (5%) 3 (7%) 2 (4%) 1 (1%)
Hyperplasia 6 (15%) 1 (3%) 2 (6%) 3 (7%) 3 (6%) 1 (1%)
Lymph Node, Mesenteric (69) (46) (48) (58) (66) (81)
Angiectasis 3 (4%) 2 (4%) 3 (6%) 4 (7%) 1 (2%)
Congestion 1 (2%) 1 (2%) 1 (1%)
Hematopoietic Cell Proliferation 2 (3%) 1 (2%) 2 (4%) 3 (5%) 2 (3%)
Hemorrhage 1 (2%) 1 (1%)
Hyperplasia 9 (13%) 17 (37%) 7 (15%) 6 (10%) 3 (5%) 1 (1%)
Hyperplasia, Histiocytic 1 (1%) 1 (1%)
Inflammation 1 (1%)
Inflammation, Granulomatous 2 (3%)
Necrosis 1 (1%)
Spleen (69) (49) (48) (58) (70) (88)
Angiectasis 1 (2%) 1 (1%)
Depletion Lymphoid 1 (1%)
Hematopoietic Cell Proliferation 27 (39%) 25 (51%) 24 (50%) 29 (50%) 28 (40%) 28 (32%)
Hemorrhage 1 (2%)
Hyperplasia, Histiocytic 1 (1%) 1 (1%)
Hyperplasia, Lymphoid 2 (3%) 3 (6%) 2 (4%) 1 (2%)
Inflammation, Focal, Granulomatous 1 (2%)
Necrosis 1 (1%)
Capsule, Inflammation, Chronic 2 (4%) 1 (1%)
Thymus (66) (46) (45) (51) (59) (81)
Angiectasis 2 (4%) 1 (2%)
Hyperplasia, Lymphoid 8 (12%) 14 (30%) 3 (7%) 2 (4%) 1 (2%)
Infiltration Cellular, Mixed Cell 1 (2%) 1 (2%)
Necrosis 1 (2%) 6 (13%) 6 (13%) 16 (31%) 22 (37%) 25 (31%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (69) (46) (49) (61) (58) (87)
Galactocele 1 (1%) 1 (2%) 1 (2%) 1 (2%)
Hyperplasia 2 (3%) 2 (4%) 5 (8%) 9 (16%) 2 (2%)
Skin (70) (50) (50) (53) (60) (89)
Acanthosis 1 (2%)
Cyst Epithelial Inclusion 1 (2%)
Inflammation, Chronic 1 (1%) 1 (2%) 2 (3%)
Necrosis 1 (2%) 1 (2%)
Hair Follicle, Atrophy 2 (4%) 3 (6%)
Subcutaneous Tissue, Edema 1 (2%)
Subcutaneous Tissue, Hemorrhage 2 (4%) 1 (2%) 1 (2%) 1 (1%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - CONT
Subcutaneous Tissue, Inflammation,
Granulomatous 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (70) (50) (50) (50) (60) (90)
Developmental Malformation 1 (1%)
Fibrous Osteodystrophy 38 (54%) 36 (72%) 29 (58%) 22 (44%) 12 (20%)
Osteopetrosis 1 (2%) 1 (2%)
Proliferation Connective Tissue 1 (1%)
Periosteum, Hemorrhage 1 (1%)
Skeletal Muscle (1) (1) (1) (2) (2)
Hemorrhage 1 (50%) 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (70) (50) (50) (50) (60) (90)
Compression 1 (1%) 1 (2%)
Hemorrhage 3 (6%) 3 (6%) 2 (3%) 6 (7%)
Infiltration Cellular, Mixed Cell 1 (1%)
Mineralization 24 (34%) 24 (48%) 17 (34%) 14 (28%) 7 (12%) 12 (13%)
Necrosis 1 (2%)
Thrombosis 1 (1%)
Perivascular, Infiltration Cellular,
Lymphocyte 3 (6%)
Ventricle, Cyst Epithelial Inclusion 1 (1%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (70) (50) (49) (47) (59) (82)
Inflammation 1 (2%) 1 (1%)
Inflammation, Suppurative 1 (1%) 1 (2%)
Lung (70) (60) (60) (70) (70) (88)
Hemorrhage 3 (4%) 4 (7%) 6 (10%) 5 (7%) 10 (14%) 13 (15%)
Hyperplasia, Lymphoid 1 (1%) 1 (2%)
Infiltration Cellular, Mixed Cell 1 (2%) 2 (3%) 3 (3%)
Inflammation, Chronic, Diffuse 1 (1%)
Inflammation, Chronic, Focal 3 (4%) 2 (3%) 1 (1%) 2 (3%)
Inflammation, Focal, Granulomatous 1 (1%)
Inflammation, Suppurative 1 (2%) 1 (1%) 1 (1%)
Thrombosis 1 (2%) 1 (1%)
Alveolar Epithelium, Hyperplasia 5 (7%) 5 (8%) 4 (7%) 11 (16%) 17 (24%) 13 (15%)
Alveolus, Infiltration Cellular, Histiocyte 1 (1%) 3 (5%) 7 (12%) 7 (10%) 10 (14%) 3 (3%)
Alveolus, Pigmentation, Hemosiderin 1 (1%) 2 (3%) 2 (3%) 1 (1%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Fat, Mediastinum, Inflammation, Chronic 1 (1%)
Fat, Mediastinum, Necrosis 1 (1%) 1 (2%)
Mediastinum, Hyperplasia, Lymphoid 1 (1%)
Peribronchiolar, Inflammation,
Pyogranulomatous 1 (1%)
Nose (70) (49) (48) (50) (60) (89)
Inflammation, Suppurative 19 (27%) 12 (24%) 13 (27%) 11 (22%) 7 (12%) 1 (1%)
Nasolacrimal Duct, Inflammation, Suppurative 2 (3%) 1 (2%) 6 (13%) 4 (8%) 1 (2%)
Olfactory Epithelium, Atrophy 2 (3%) 7 (8%)
Olfactory Epithelium, Inflammation, Chronic 1 (1%)
Respiratory Epithelium, Hyperplasia 1 (2%)
Respiratory Epithelium, Metaplasia, Squamous 1 (1%) 2 (3%)
Trachea (69) (50) (48) (49) (60) (83)
Inflammation, Suppurative 13 (19%) 17 (34%) 14 (29%) 10 (20%) 8 (13%)
Metaplasia, Squamous 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (3) (2) (2) (3) (3)
Degeneration 2 (67%) 1 (50%)
Cornea, Hyperplasia 1 (50%) 1 (33%)
Cornea, Inflammation, Chronic 1 (50%) 1 (50%) 2 (67%)
Lens, Degeneration 2 (100%)
Harderian Gland (64) (50) (49) (59) (60) (73)
Hyperplasia 1 (2%) 5 (10%) 9 (18%) 4 (7%) 5 (8%) 7 (10%)
Inflammation, Chronic 1 (2%) 1 (2%) 1 (1%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (69) (49) (48) (50) (60) (90)
Amyloid Deposition 1 (2%)
Glomerulosclerosis 1 (1%)
Hematopoietic Cell Proliferation 1 (2%) 2 (3%)
Hydronephrosis 2 (3%) 2 (4%) 2 (3%)
Infarct 1 (2%)
Infiltration Cellular, Lymphocyte 1 (1%) 1 (2%)
Inflammation, Suppurative 1 (1%) 1 (2%)
Metaplasia, Osseous 1 (1%) 1 (2%) 2 (4%) 2 (3%) 1 (1%)
Nephropathy 11 (16%) 3 (6%) 3 (6%) 6 (12%) 1 (2%)
Pigmentation, Hemosiderin 2 (4%)
Thrombosis 1 (1%)
Capsule, Inflammation, Chronic 1 (2%)
Medulla, Congestion 1 (2%)
Renal Tubule, Degeneration 1 (2%)
Renal Tubule, Hyperplasia 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Renal Tubule, Mineralization 1 (2%)
Urinary Bladder (67) (46) (48) (46) (59) (85)
Hemorrhage 3 (4%)
Hyperplasia, Histiocytic 1 (1%)
Inflammation 2 (3%) 1 (2%)
Transitional Epithelium, Hyperplasia 1 (1%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 70 70 70 70 70 50
Scheduled Sacrifice 20 20 20 20 20
Early Deaths
Dead 6 5 11 12 23 12
Moribund 9 6 15 15 23 29
Survivors
Terminal Sacrifice 35 39 24 22 3 9
Dead 1
Missing 1
Animals Examined Microscopically 70 70 70 70 70 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (64) (47) (39) (36) (42) (40)
Hyperplasia 2 (4%) 1 (2%) 1 (3%)
Inflammation 1 (2%)
Intestine Large, Cecum (70) (46) (42) (44) (50) (42)
Angiectasis 1 (2%)
Inflammation 1 (1%)
Intestine Large, Rectum (70) (47) (46) (48) (55) (44)
Hemorrhage 1 (2%)
Intestine Small (69) (48) (44) (47) (49) (44)
Epithelium, Hyperplasia 1 (2%)
Intestine Small, Duodenum (67) (46) (42) (44) (47) (42)
Angiectasis 1 (2%)
Hemorrhage 1 (2%)
Inflammation, Chronic 1 (2%)
Pigmentation, Hemosiderin 1 (2%)
Ulcer 1 (1%)
Peyer's Patch, Hyperplasia 1 (1%) 1 (2%)
Intestine Small, Ileum (68) (48) (43) (46) (47) (44)
Peyer's Patch, Hyperplasia 2 (4%) 2 (4%)
Intestine Small, Jejunum (68) (46) (43) (44) (43) (43)
Cyst 1 (2%)
Inflammation, Chronic 1 (2%)
Pigmentation, Hemosiderin 1 (2%)
Peyer's Patch, Hyperplasia 2 (4%) 3 (7%) 1 (2%) 1 (2%)
Peyer's Patch, Inflammation, Granulomatous 1 (1%)
Liver (70) (61) (61) (60) (68) (49)
Angiectasis 4 (7%) 3 (5%) 1 (2%)
Basophilic Focus 3 (4%) 3 (5%) 3 (5%) 5 (8%) 1 (1%) 3 (6%)
Clear Cell Focus 2 (3%) 1 (2%) 1 (2%) 1 (2%)
Degeneration, Fatty 4 (7%) 3 (5%) 1 (1%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Developmental Malformation 1 (2%) 1 (1%)
Eosinophilic Focus 3 (4%) 6 (10%) 4 (7%) 3 (5%) 4 (6%) 1 (2%)
Focal Cellular Change 1 (2%)
Hematopoietic Cell Proliferation 1 (2%) 3 (5%) 4 (6%) 1 (2%)
Infarct 1 (1%) 5 (8%) 3 (5%) 2 (4%)
Inflammation, Chronic 1 (1%) 1 (2%)
Inflammation, Focal, Granulomatous 1 (2%) 1 (1%) 2 (4%)
Mineralization 1 (1%)
Mixed Cell Focus 2 (3%) 2 (3%) 1 (2%) 4 (7%) 1 (1%) 1 (2%)
Necrosis 4 (6%) 5 (8%) 8 (13%) 13 (22%) 14 (21%) 8 (16%)
Biliary Tract, Cyst 1 (2%)
Biliary Tract, Hyperplasia 1 (1%)
Centrilobular, Degeneration, Fatty 15 (21%) 6 (10%) 10 (16%) 9 (15%) 12 (18%) 1 (2%)
Centrilobular, Necrosis 2 (3%)
Mesentery (6) (5) (9) (14) (10) (13)
Fat, Angiectasis 1 (17%) 2 (40%) 4 (44%) 6 (43%) 3 (30%) 6 (46%)
Fat, Hemorrhage 1 (11%) 3 (21%) 1 (10%)
Fat, Inflammation, Chronic 1 (20%) 5 (56%) 2 (14%) 5 (50%) 3 (23%)
Fat, Inflammation, Granulomatous 1 (17%)
Fat, Necrosis 2 (33%) 2 (40%) 4 (44%) 2 (14%) 1 (10%) 1 (8%)
Pancreas (70) (49) (49) (58) (66) (46)
Acinus, Angiectasis 1 (2%)
Acinus, Atrophy 1 (1%) 2 (4%) 1 (2%) 1 (2%)
Acinus, Focal Cellular Change 1 (2%) 5 (10%) 4 (7%) 4 (6%) 3 (7%)
Acinus, Hyperplasia 1 (1%) 1 (2%)
Acinus, Inflammation, Chronic 1 (2%)
Acinus, Necrosis 2 (4%)
Pharynx (1) (1) (1)
Epithelium, Hyperplasia 1 (100%) 1 (100%)
Palate, Inflammation, Chronic 1 (100%)
Salivary Glands (70) (50) (50) (48) (58) (48)
Inflammation 1 (1%)
Inflammation, Chronic 1 (2%)
Stomach, Forestomach (70) (50) (60) (60) (68) (48)
Angiectasis 1 (2%)
Cyst Epithelial Inclusion 1 (2%)
Hyperplasia, Mast Cell 1 (1%)
Ulcer 3 (4%) 2 (3%) 5 (8%) 4 (6%) 3 (6%)
Epithelium, Hyperplasia 4 (6%) 3 (6%) 3 (5%) 8 (13%) 6 (9%) 10 (21%)
Stomach, Glandular (70) (48) (60) (60) (65) (44)
Inflammation, Suppurative 1 (2%) 2 (3%)
Mineralization 1 (2%)
Pigmentation, Hemosiderin 2 (3%) 2 (4%) 3 (5%) 5 (8%) 10 (15%) 2 (5%)
Ulcer 3 (4%) 1 (2%) 6 (10%) 9 (14%) 2 (5%)
Tooth (9) (4) (6) (3) (1) (6)
Developmental Malformation 1 (33%)
Inflammation 9 (100%) 4 (100%) 6 (100%) 2 (67%) 1 (100%) 6 (100%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (1)
Inflammation 1 (100%)
Heart (70) (50) (60) (58) (68) (50)
Cardiomyopathy 4 (6%) 1 (2%) 6 (10%) 3 (5%) 2 (3%) 2 (4%)
Inflammation, Suppurative 1 (1%) 2 (4%) 1 (2%) 1 (2%) 1 (1%)
Mineralization 2 (3%) 1 (2%) 3 (4%)
Necrosis 1 (2%) 2 (3%)
Atrium, Thrombosis 1 (1%)
Endothelium, Hyperplasia 1 (2%) 2 (3%) 5 (7%) 6 (12%)
Pericardium, Inflammation, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (70) (49) (50) (47) (58) (45)
Cyst 2 (4%) 1 (2%)
Focal Cellular Change 6 (9%) 13 (27%) 8 (16%) 12 (26%) 4 (9%)
Hyperplasia 6 (9%) 8 (16%) 1 (2%) 3 (6%) 4 (7%) 5 (11%)
Hypertrophy 19 (27%) 16 (33%) 14 (28%) 11 (23%) 6 (10%) 10 (22%)
Adrenal Gland, Medulla (70) (48) (47) (44) (54) (45)
Hyperplasia 1 (2%) 1 (2%) 1 (2%)
Islets, Pancreatic (70) (49) (49) (58) (65) (46)
Hyperplasia 2 (3%) 8 (16%) 4 (8%) 3 (5%) 6 (9%) 3 (7%)
Parathyroid Gland (58) (36) (42) (40) (48) (40)
Cyst 1 (2%) 1 (3%)
Pituitary Gland (69) (47) (47) (48) (56) (44)
Pars Distalis, Cyst 1 (1%) 1 (2%) 4 (9%) 2 (4%) 1 (2%) 1 (2%)
Pars Distalis, Hyperplasia 1 (2%) 2 (4%) 1 (2%)
Pars Intermedia, Hyperplasia 1 (2%)
Thyroid Gland (70) (50) (50) (48) (57) (48)
Cyst 3 (6%) 1 (2%) 4 (8%) 3 (5%) 1 (2%)
Hemorrhage 1 (2%)
Hyperplasia 1 (1%)
Inflammation 2 (3%) 1 (2%)
C-Cell, Hyperplasia 1 (2%)
Follicular Cell, Hyperplasia 1 (1%) 11 (22%) 4 (8%) 5 (10%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (70) (50) (50) (48) (59) (49)
Angiectasis 1 (2%)
Degeneration 2 (4%)
Hypospermia 1 (2%) 4 (8%)
Inflammation, Chronic 1 (1%) 2 (4%) 3 (6%) 2 (4%) 1 (2%)
Muscularis, Hyperplasia 1 (1%) 1 (2%)
Penis (4) (1) (4) (7) (1) (4)
Hyperplasia 1 (25%)
Inflammation, Suppurative 1 (25%) 1 (100%) 3 (75%) 2 (29%) 1 (100%) 1 (25%)
Preputial Gland (8) (2) (4) (9) (6) (8)
Degeneration, Cystic 1 (13%) 1 (25%) 3 (33%) 1 (17%) 1 (13%)
Hyperplasia 2 (25%)
Inflammation, Suppurative 7 (88%) 2 (100%) 1 (25%) 2 (22%) 3 (38%)
Duct, Dilatation 2 (50%) 1 (11%) 1 (13%)
Prostate (67) (50) (48) (45) (56) (44)
Hyperplasia 2 (4%) 1 (2%) 1 (2%)
Inflammation 1 (2%)
Inflammation, Suppurative 3 (4%) 2 (4%) 5 (10%) 2 (4%) 1 (2%) 3 (7%)
Seminal Vesicle (70) (48) (47) (46) (54) (44)
Inflammation, Suppurative 3 (4%) 1 (2%) 1 (2%) 2 (5%)
Testes (70) (50) (51) (48) (69) (50)
Angiectasis 1 (1%)
Atrophy 1 (1%) 3 (6%) 4 (8%) 2 (4%) 6 (9%) 5 (10%)
Degeneration 1 (1%) 3 (6%) 1 (1%) 2 (4%)
Hemorrhage 1 (1%)
Mineralization 1 (2%) 2 (4%) 2 (4%)
Spermatocele 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (70) (50) (50) (58) (69) (50)
Angiectasis 1 (2%)
Hyperplasia 14 (20%) 5 (10%) 7 (14%) 17 (29%) 14 (20%) 9 (18%)
Infiltration Cellular, Mast Cell 1 (1%)
Lymph Node (70) (50) (50) (57) (68) (50)
Hyperplasia 1 (2%) 1 (1%)
Iliac, Hyperplasia 1 (2%) 1 (2%)
Lymph Node, Bronchial (64) (42) (42) (40) (46) (43)
Congestion 1 (2%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%)
Hyperplasia 2 (5%) 4 (10%) 1 (3%) 3 (7%) 5 (12%)
Lymph Node, Mandibular (55) (39) (38) (37) (53) (42)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia 5 (9%) 5 (13%) 1 (3%) 4 (11%) 9 (17%) 9 (21%)
Lymph Node, Mediastinal (37) (27) (33) (39) (48) (39)
a Number of animals examined microscopically at site and number of animals with lesion
Page 13
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Congestion 2 (5%)
Hematopoietic Cell Proliferation 1 (4%) 1 (3%) 1 (3%) 1 (3%)
Hyperplasia 3 (8%) 2 (7%) 4 (12%) 3 (6%) 1 (3%)
Inflammation 1 (3%)
Lymph Node, Mesenteric (68) (47) (47) (55) (65) (44)
Angiectasis 2 (3%) 9 (19%) 5 (11%) 8 (15%) 7 (11%) 7 (16%)
Congestion 4 (6%) 7 (15%) 4 (9%) 12 (22%) 6 (9%) 2 (5%)
Hematopoietic Cell Proliferation 1 (1%) 7 (15%) 1 (2%) 4 (7%) 5 (8%) 5 (11%)
Hemorrhage 1 (1%) 1 (2%) 1 (2%)
Hyperplasia 11 (16%) 17 (36%) 12 (26%) 8 (15%) 5 (8%) 3 (7%)
Inflammation 1 (2%)
Inflammation, Granulomatous 1 (2%)
Spleen (70) (50) (51) (58) (66) (47)
Depletion Lymphoid 1 (2%)
Hematopoietic Cell Proliferation 10 (14%) 15 (30%) 9 (18%) 23 (40%) 21 (32%) 12 (26%)
Hyperplasia, Histiocytic 1 (2%)
Hyperplasia, Lymphoid 3 (6%) 2 (3%)
Necrosis 1 (2%) 1 (2%)
Pigmentation, Melanin 1 (2%)
Thrombosis 1 (2%)
Thymus (66) (43) (42) (51) (55) (41)
Hyperplasia, Lymphoid 1 (2%) 1 (2%) 2 (4%)
Infiltration Cellular, Mixed Cell 1 (2%)
Necrosis 13 (20%) 7 (16%) 18 (43%) 18 (35%) 19 (35%) 14 (34%)
Epithelial Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (70) (50) (51) (49) (60) (50)
Acanthosis 1 (2%)
Cyst Epithelial Inclusion 1 (2%)
Inflammation, Chronic 1 (2%) 4 (8%) 3 (5%) 2 (4%)
Foot, Developmental Malformation 1 (2%)
Hair Follicle, Atrophy 1 (2%) 1 (2%)
Prepuce, Inflammation, Suppurative 2 (3%) 3 (6%) 7 (14%) 7 (14%) 2 (3%) 5 (10%)
Sebaceous Gland, Hyperplasia 1 (2%)
Subcutaneous Tissue, Angiectasis 1 (2%) 2 (4%) 1 (2%) 2 (3%) 1 (2%)
Subcutaneous Tissue, Edema 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemorrhage 1 (2%)
Subcutaneous Tissue, Inflammation, Chronic 1 (2%)
Subcutaneous Tissue, Inflammation,
Granulomatous 1 (1%) 1 (2%)
Subcutaneous Tissue, Inflammation,
Pyogranulomatous 1 (1%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 14
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (70) (50) (50) (49) (60) (50)
Developmental Malformation 2 (4%)
Fibrous Osteodystrophy 1 (1%)
Fracture 1 (2%)
Osteopetrosis 1 (2%) 1 (2%) 1 (2%)
Cranium, Hemorrhage 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (70) (50) (50) (48) (60) (50)
Developmental Malformation 1 (1%)
Hemorrhage 1 (2%) 2 (3%) 4 (8%)
Inflammation, Chronic 1 (2%)
Mineralization 33 (47%) 27 (54%) 16 (32%) 15 (31%) 11 (18%) 15 (30%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (70) (48) (49) (46) (53) (46)
Inflammation, Suppurative 3 (4%) 5 (10%) 2 (4%) 4 (9%) 1 (2%) 1 (2%)
Lung (70) (52) (62) (69) (70) (50)
Angiectasis 1 (2%)
Hemorrhage 1 (1%) 6 (12%) 7 (11%) 3 (4%) 6 (9%) 3 (6%)
Hyperplasia, Lymphoid 1 (2%)
Inflammation, Chronic, Diffuse 2 (3%) 1 (2%)
Inflammation, Chronic, Focal 1 (2%) 1 (1%)
Inflammation, Suppurative 1 (1%) 2 (4%)
Thrombosis 1 (1%) 1 (1%)
Alveolar Epithelium, Hyperplasia 2 (3%) 10 (19%) 6 (10%) 14 (20%) 23 (33%) 18 (36%)
Alveolus, Infiltration Cellular, Histiocyte 10 (14%) 4 (8%) 7 (11%) 6 (9%) 12 (17%) 18 (36%)
Perivascular, Inflammation, Chronic 1 (2%)
Pleura, Inflammation, Chronic 1 (2%) 1 (2%)
Nose (70) (50) (50) (47) (59) (49)
Inflammation, Suppurative 21 (30%) 15 (30%) 21 (42%) 15 (32%) 8 (14%) 14 (29%)
Inflammation, Pyogranulomatous 1 (2%)
Nasolacrimal Duct, Inflammation, Suppurative 2 (3%) 2 (4%) 1 (2%) 9 (19%) 9 (15%) 6 (12%)
Olfactory Epithelium, Atrophy 1 (2%) 1 (2%) 1 (2%)
Respiratory Epithelium, Metaplasia, Squamous 1 (1%)
Trachea (70) (49) (50) (46) (55) (47)
Inflammation, Suppurative 25 (36%) 24 (49%) 19 (38%) 19 (41%) 12 (22%) 20 (43%)
Metaplasia, Squamous 1 (1%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 15
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (1) (3) (8) (1)
Degeneration 1 (13%)
Cornea, Hyperplasia 3 (38%)
Cornea, Inflammation, Chronic 1 (100%) 6 (75%)
Lens, Degeneration 1 (100%) 1 (33%) 1 (13%)
Harderian Gland (63) (59) (60) (57) (61) (48)
Hyperplasia 1 (2%) 3 (5%) 4 (7%) 6 (11%) 14 (23%) 4 (8%)
Inflammation, Suppurative 1 (2%)
Zymbal's Gland (2) (1)
Cyst 1 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (70) (53) (54) (50) (69) (48)
Cyst 4 (6%) 8 (15%) 1 (2%) 2 (4%) 1 (1%)
Hydronephrosis 2 (4%) 1 (2%) 1 (2%)
Hyperplasia, Mast Cell 1 (1%)
Infarct 1 (2%) 1 (2%) 1 (1%)
Infiltration Cellular, Histiocyte 1 (2%)
Inflammation, Suppurative 1 (1%) 1 (2%) 4 (7%) 1 (2%) 3 (4%) 1 (2%)
Metaplasia, Osseous 1 (1%) 1 (2%)
Nephropathy 35 (50%) 38 (72%) 26 (48%) 20 (40%) 13 (19%) 12 (25%)
Pigmentation, Hemosiderin 1 (2%)
Capsule, Inflammation, Chronic 1 (2%)
Papilla, Necrosis 1 (1%) 2 (4%)
Renal Tubule, Hyperplasia 2 (3%) 3 (6%) 1 (1%) 4 (8%)
Renal Tubule, Mineralization 2 (4%)
Urethra (2) (2) (1) (6) (2) (1)
Inflammation, Suppurative 1 (50%) 1 (100%) 1 (50%)
Necrosis 1 (50%)
Urinary Bladder (70) (48) (50) (49) (58) (43)
Calculus Micro Observation Only 1 (2%)
Dilatation 9 (13%) 3 (6%) 8 (16%) 8 (16%) 5 (9%) 8 (19%)
Inflammation 1 (1%) 1 (2%) 3 (6%) 1 (2%) 1 (2%)
Necrosis 1 (2%)
Transitional Epithelium, Hyperplasia 1 (2%) 2 (5%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 16
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 90 50 50
Scheduled Sacrifice 17
Early Deaths
Moribund 25 33 25 22
Dead 24 39 19 28
Accident 1 1
Survivors
Terminal Sacrifice 1 5
Animals Examined Microscopically 50 90 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (27) (57) (32) (32)
Hyperplasia 1 (3%)
Intestine Large (48) (82) (46) (47)
Anus, Inflammation, Suppurative 1 (1%)
Intestine Large, Colon (44) (78) (44) (45)
Necrosis 1 (1%) 1 (2%)
Intestine Small, Duodenum (38) (67) (35) (32)
Hemorrhage 1 (1%) 1 (3%)
Intestine Small, Ileum (40) (68) (37) (40)
Angiectasis 1 (3%)
Peyer's Patch, Hyperplasia 1 (3%)
Intestine Small, Jejunum (37) (65) (40) (41)
Hemorrhage 1 (2%)
Peyer's Patch, Necrosis 1 (2%)
Liver (50) (89) (49) (50)
Angiectasis 1 (2%) 1 (2%)
Basophilic Focus 2 (4%) 2 (2%) 1 (2%)
Degeneration, Fatty 1 (2%) 2 (2%) 2 (4%)
Eosinophilic Focus 4 (8%) 1 (1%) 1 (2%) 3 (6%)
Hematopoietic Cell Proliferation 4 (8%) 7 (8%) 3 (6%) 9 (18%)
Hyperplasia, Focal 1 (1%)
Infarct 1 (2%) 3 (6%)
Inflammation, Chronic 1 (2%)
Inflammation, Focal, Granulomatous 1 (2%)
Mineralization 2 (2%)
Necrosis 13 (26%) 19 (21%) 10 (20%) 14 (28%)
Thrombosis 2 (4%)
Biliary Tract, Cyst 2 (4%)
Biliary Tract, Hyperplasia 2 (4%)
Biliary Tract, Hypertrophy 1 (2%)
Centrilobular, Degeneration, Fatty 4 (8%) 8 (9%) 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 17
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Centrilobular, Necrosis 7 (14%) 7 (8%) 1 (2%) 1 (2%)
Mesentery (13) (6) (11) (4)
Fat, Angiectasis 3 (23%) 2 (18%)
Fat, Hemorrhage 1 (8%) 1 (17%) 1 (9%) 1 (25%)
Fat, Inflammation, Chronic 1 (8%) 2 (33%)
Fat, Necrosis 1 (17%) 2 (18%) 1 (25%)
Pancreas (49) (89) (46) (49)
Acinus, Atrophy 1 (2%) 1 (2%)
Acinus, Focal Cellular Change 2 (4%) 3 (3%)
Acinus, Hyperplasia 3 (6%)
Acinus, Inflammation, Chronic 1 (1%)
Acinus, Vacuolization Cytoplasmic 1 (2%)
Pharynx (2) (2)
Palate, Inflammation, Chronic 1 (50%)
Salivary Glands (48) (86) (50) (50)
Hemorrhage 1 (1%)
Infiltration Cellular, Mixed Cell 1 (2%)
Inflammation 2 (4%)
Stomach, Forestomach (48) (89) (50) (50)
Hemorrhage 1 (1%)
Ulcer 4 (8%) 13 (15%) 2 (4%) 2 (4%)
Epithelium, Hyperplasia 20 (42%) 50 (56%) 8 (16%) 15 (30%)
Stomach, Glandular (47) (83) (44) (47)
Mineralization 1 (1%)
Pigmentation, Hemosiderin 7 (15%) 7 (8%) 3 (7%) 4 (9%)
Ulcer 3 (6%) 6 (7%) 1 (2%) 4 (9%)
Tooth (4)
Inflammation 3 (75%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (1)
Mineralization 1 (100%)
Heart (50) (90) (50) (50)
Cardiomyopathy 1 (2%) 2 (2%) 1 (2%) 4 (8%)
Hemorrhage 2 (2%) 1 (2%)
Inflammation, Suppurative 2 (4%)
Mineralization 6 (12%) 21 (23%) 9 (18%) 14 (28%)
Necrosis 1 (2%) 1 (1%) 1 (2%)
Atrium, Thrombosis 1 (2%) 3 (3%) 1 (2%)
Endothelium, Hyperplasia 3 (6%) 8 (9%) 7 (14%) 7 (14%)
Pericardium, Inflammation, Chronic 1 (2%)
Ventricle, Thrombosis 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 18
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (49) (90) (50) (50)
Focal Cellular Change 1 (2%)
Hematocyst 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia 4 (8%) 1 (2%)
Hypertrophy 12 (24%) 5 (6%) 9 (18%) 2 (4%)
Adrenal Gland, Medulla (48) (86) (49) (48)
Hematopoietic Cell Proliferation 1 (2%)
Islets, Pancreatic (49) (87) (45) (48)
Cytoplasmic Alteration 1 (2%)
Hyperplasia 1 (2%) 1 (1%) 1 (2%)
Parathyroid Gland (44) (69) (33) (37)
Cyst 2 (3%)
Pituitary Gland (43) (78) (43) (43)
Pars Distalis, Cyst 1 (2%) 1 (1%) 2 (5%)
Pars Distalis, Hemorrhage 1 (2%)
Pars Distalis, Hyperplasia 1 (2%)
Thyroid Gland (49) (86) (50) (49)
Cyst 3 (6%) 1 (2%) 1 (2%)
Follicular Cell, Hyperplasia 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (2)
Inflammation, Suppurative 2 (100%)
Epididymis (50) (87) (49) (50)
Angiectasis 1 (1%) 1 (2%)
Infiltration Cellular, Mixed Cell 1 (2%)
Inflammation, Chronic 3 (6%) 1 (2%)
Preputial Gland (4) (2) (10) (6)
Angiectasis 1 (25%)
Degeneration, Cystic 1 (10%)
Hyperplasia 2 (20%)
Inflammation, Suppurative 2 (100%) 6 (60%) 3 (50%)
Prostate (48) (83) (48) (47)
Hyperplasia 1 (1%)
Inflammation 1 (1%) 1 (2%)
Inflammation, Suppurative 1 (1%) 2 (4%)
Mineralization 1 (1%)
Seminal Vesicle (47) (84) (42) (47)
a Number of animals examined microscopically at site and number of animals with lesion
Page 19
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Inflammation, Suppurative 1 (2%)
Testes (50) (89) (50) (50)
Angiectasis 4 (8%) 1 (2%)
Atrophy 3 (6%) 63 (71%) 3 (6%) 5 (10%)
Degeneration 2 (4%)
Interstitial Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (90) (48) (49)
Angiectasis 1 (2%)
Atrophy 5 (10%) 28 (31%) 3 (6%) 2 (4%)
Fibrosis 1 (2%)
Hyperplasia 9 (18%) 5 (6%) 11 (23%) 8 (16%)
Hyperplasia, Histiocytic 1 (1%)
Infiltration Cellular, Megakaryocyte 1 (1%)
Necrosis 1 (1%) 1 (2%)
Lymph Node (50) (90) (49) (50)
Necrosis 1 (1%)
Axillary, Hematopoietic Cell Proliferation 1 (2%)
Iliac, Hematopoietic Cell Proliferation 1 (2%)
Iliac, Hyperplasia 1 (2%)
Inguinal, Hematopoietic Cell Proliferation 1 (2%)
Pancreatic, Hyperplasia 1 (2%)
Renal, Mineralization 1 (1%)
Lymph Node, Bronchial (37) (53) (40) (41)
Hematopoietic Cell Proliferation 2 (5%) 2 (5%)
Hyperplasia 1 (3%) 1 (3%)
Lymph Node, Mandibular (31) (70) (39) (43)
Hematopoietic Cell Proliferation 1 (1%) 2 (5%)
Hyperplasia 3 (10%) 7 (18%)
Hyperplasia, Histiocytic 2 (3%)
Hyperplasia, Plasma Cell 4 (6%)
Mineralization 2 (3%)
Necrosis 6 (9%) 1 (2%)
Lymph Node, Mediastinal (41) (68) (39) (44)
Congestion 1 (1%) 1 (2%)
Hematopoietic Cell Proliferation 2 (5%) 2 (3%) 3 (7%)
Hyperplasia 2 (5%) 1 (3%)
Lymph Node, Mesenteric (44) (84) (43) (48)
Angiectasis 1 (2%) 2 (5%) 1 (2%)
Congestion 1 (2%) 2 (5%)
Hematopoietic Cell Proliferation 2 (5%) 4 (9%) 1 (2%)
Hemorrhage 1 (1%)
Hyperplasia 1 (2%)
Hyperplasia, Histiocytic 3 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 20
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Inflammation 1 (1%) 1 (2%)
Necrosis 1 (1%)
Spleen (48) (87) (49) (50)
Angiectasis 1 (2%)
Depletion Lymphoid 1 (2%) 2 (2%)
Hematopoietic Cell Proliferation 21 (44%) 16 (18%) 18 (37%) 18 (36%)
Hemorrhage 1 (2%)
Hyperplasia, Histiocytic 2 (2%)
Hyperplasia, Lymphoid 2 (4%)
Mineralization 1 (1%)
Necrosis 2 (2%) 1 (2%)
Thymus (37) (78) (37) (40)
Hyperplasia, Neutrophil 1 (1%)
Infiltration Cellular, Mixed Cell 1 (3%)
Inflammation, Suppurative 1 (3%)
Necrosis 30 (81%) 17 (22%) 10 (27%) 10 (25%)
Mediastinum, Necrosis 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (49) (90) (50) (50)
Acanthosis 1 (1%)
Cyst Epithelial Inclusion 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Necrosis 1 (1%)
Hair Follicle, Atrophy 1 (2%) 1 (2%)
Hair Follicle, Inflammation, Suppurative 1 (1%)
Prepuce, Inflammation, Suppurative 1 (1%) 2 (4%)
Sebaceous Gland, Hyperplasia 1 (2%)
Subcutaneous Tissue, Angiectasis 1 (2%)
Subcutaneous Tissue, Edema 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemorrhage 3 (6%) 1 (1%) 2 (4%) 1 (2%)
Subcutaneous Tissue, Inflammation,
Granulomatous 2 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 21
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (90) (50) (50)
Hemorrhage 6 (12%) 12 (13%) 2 (4%) 3 (6%)
Mineralization 9 (18%) 9 (10%) 12 (24%) 6 (12%)
Necrosis 1 (2%) 2 (4%)
Pigmentation, Hemosiderin 1 (2%)
Spinal Cord (12) (1) (2)
Hemorrhage 2 (17%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (49) (88) (49) (47)
Hyperplasia 1 (1%)
Inflammation 1 (1%)
Inflammation, Suppurative 1 (2%)
Metaplasia, Squamous 1 (2%)
Lung (50) (90) (50) (50)
Hemorrhage 7 (14%) 14 (16%) 5 (10%) 10 (20%)
Inflammation, Chronic, Focal 1 (2%) 1 (2%) 2 (4%)
Inflammation, Suppurative 2 (4%)
Thrombosis 1 (1%) 1 (2%)
Alveolar Epithelium, Hyperplasia 14 (28%) 22 (24%) 10 (20%) 11 (22%)
Alveolus, Infiltration Cellular, Histiocyte 12 (24%) 2 (2%) 9 (18%) 3 (6%)
Alveolus, Pigmentation, Hemosiderin 1 (2%) 1 (1%) 1 (2%)
Bronchiole, Epithelium, Hyperplasia 1 (2%)
Pleura, Inflammation, Chronic 1 (1%) 1 (2%)
Nose (49) (88) (50) (50)
Inflammation, Suppurative 7 (14%) 2 (2%) 7 (14%) 1 (2%)
Nasolacrimal Duct, Inflammation, Suppurative 8 (16%) 8 (16%) 1 (2%)
Nerve, Hyperplasia 1 (2%)
Olfactory Epithelium, Atrophy 2 (4%) 4 (5%) 2 (4%) 1 (2%)
Olfactory Epithelium, Metaplasia, Squamous 2 (2%)
Respiratory Epithelium, Metaplasia, Squamous 1 (2%)
Trachea (47) (84) (48) (48)
Inflammation, Suppurative 12 (26%) 11 (23%) 7 (15%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (4) (6) (4) (3)
Degeneration 1 (17%) 1 (25%)
Cornea, Hyperplasia 1 (25%)
Cornea, Inflammation, Chronic 2 (50%) 2 (50%)
Harderian Gland (48) (53) (42) (36)
Hyperplasia 6 (13%) 5 (9%) 3 (7%) 7 (19%)
Inflammation, Chronic 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 22
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:58
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (90) (50) (50)
Cyst 1 (2%) 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hemorrhage 2 (2%) 1 (2%) 2 (4%)
Hydronephrosis 1 (1%)
Infarct 1 (2%)
Inflammation, Suppurative 1 (1%) 4 (8%) 1 (2%)
Metaplasia, Osseous 1 (2%)
Nephropathy 4 (8%) 5 (6%) 10 (20%) 4 (8%)
Capsule, Angiectasis 1 (2%)
Capsule, Inflammation, Chronic 1 (2%)
Papilla, Necrosis 1 (1%)
Pelvis, Hyperplasia 2 (2%)
Pelvis, Mineralization 3 (3%)
Renal Tubule, Hyperplasia 1 (2%) 1 (1%) 1 (2%) 2 (4%)
Renal Tubule, Mineralization 4 (4%) 1 (2%)
Urinary Bladder (47) (83) (46) (48)
Dilatation 1 (1%) 3 (7%)
Hemorrhage 1 (1%)
Inflammation 3 (4%) 1 (2%)
Transitional Epithelium, Hyperplasia 1 (2%) 2 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 23
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------